Papel del ácido ursodesoxicólico en 40 años de tratamiento para la colangitis biliar primaria
DOI:
https://doi.org/10.59093/27112322.174Palabras clave:
ácido ursodesoxicólico, colangitis biliar primaria, tratamiento, ácidos biliares, bilis.Resumen
La colangitis biliar primaria es una enfermedad hepática autoinmune que conduce a la destrucción progresiva de los conductos biliares intrahepáticos, lo que aumenta el riesgo de desarrollar cirrosis e hipertensión portal. Actualmente, el ácido ursodesoxicólico es el medicamento de primera línea para el tratamiento de esta entidad. Este medicamento desplaza los ácidos biliares hidrofóbicos y aumenta las concentraciones de ácidos biliares hidrofílicos en la bilis, lo cual favorece la integridad de los conductos biliares, adicionalmente, tiene efectos antiinflamatorios y propiedades inmunomoduladoras y antiapoptóticas. En los últimos 40 años, numerosos ensayos clínicos han respaldado la eficacia clínica del ácido ursodesoxicólico y su seguridad cuando se utiliza en pacientes con colangitis biliar primaria. Se realiza una revisión del ácido ursodesoxicólico en el contexto de colangitis biliar primaria, se describe su historia, mecanismos de acción, efectos secundarios y dosificación. Finalmente, se menciona su uso en situaciones especiales como son el embarazo y la lactancia.
Descargas
Referencias bibliográficas
Prieto J, Banales JM, Medina JF. Primary biliary cholangitis: pathogenic mechanisms. Curr Opin Gastroenterol 2021;37:91-98. https://doi.org/10.1097/mog.0000000000000703.
Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol 2021;27:1-21. https://doi.org/10.3350/cmh.2020.0028.
Alvaro D, Carpino G, Craxi A, Floreani A, Moschetta A, Invernizzi P. Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Liver Int 2020;40:2590-2601. https://doi.org/10.1111/liv.14627.
Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1423-1434. https://doi.org/10.1111/jgh.15329.
Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther 2020;52:1150-1164. https://doi.org/10.1111/apt.16023.
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386:1565-1575. https://doi.org/10.1016/s0140-6736(15)00154-3.
Abai B, Samant H. Primary biliary cholangitis. StatPearls. Treasure Island, FL: StatPearls; 2022. Acceso 26 de diciembre de 2022. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK459209.
Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145-172. https://doi.org/10.1016/j.jhep.2017.03.022.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 2020;396:1915-1926. https://doi.org/10.1016/s0140-6736(20)31607-x.
Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524-1529. https://doi.org/10.1056/NEJMct074694.
Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013;144:560-569.e567. https://doi.org/10.1053/j.gastro.2012.12.005.
Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 2020;17:93-110. https://doi.org/10.1038/s41575-019-0226-7.
Örnolfsson KT, Olafsson S, Bergmann OM, Gershwin ME, Björnsson ES. Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis. Hepatology 2018;68:166-171. https://doi.org/10.1002/hep.29675.
Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018;67:534-541. https://doi.org/10.1136/gutjnl-2016-313332.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-1202. https://doi.org/10.1002/hep.20907.
Phaw NA, Dyson JK, Mells G, Jones D. Understanding fatigue in primary biliary cholangitis. Dig Dis Sci 2021;66:2380-2386. https://doi.org/10.1007/s10620-020-06502-0.
Gossard AA, Lindor KD. Current and promising therapy for primary biliary cholangitis. Expert Opin Pharmacother 2019;20:1161-1167. https://doi.org/10.1080/14656566.2019.1601701.
Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol 2020;5:306-315. https://doi.org/10.1016/s2468-1253(19)30343-7.
Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, et al. Clinical management of primary biliary cholangitis-strategies and evolving trends. Clin Rev Allergy Immunol 2020;59:175-194. https://doi.org/10.1007/s12016-019-08772-7.
Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis 2015;33:S2-12. https://doi.org/10.1159/000440705.
Kuiper EM, Hansen BE, Metselaar HJ, de Man RA, Haagsma EB, van Hoek B, et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010;10:144. https://doi.org/10.1186/1471-230x-10-144.
Wang JY, Wu SD. Chapter 55 - Ursodeoxycholic acid for the treatment of liver diseases. In: Muriel P, ed. Liver Pathophysiology. Boston: Academic Press; 2017. p. 767-779. https://doi.org/https://doi.org/10.1016/B978-0-12-804274-8.00055-2.
Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1:834-836. https://doi.org/10.1016/s0140-6736(87)91610-2.
Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-1554. https://doi.org/10.1056/nejm199105303242204.
Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-1156.
Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-1347. https://doi.org/10.1056/nejm199405123301903.
Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890. https://doi.org/10.1016/s0016-5085(97)70183-5.
Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002;1:Cd000551. https://doi.org/10.1002/14651858.Cd000551.
Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-720. https://doi.org/10.1053/j.gastro.2005.12.029.
Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349.e1335. https://doi.org/10.1053/j.gastro.2014.08.029.
Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J 2020;8:667-674. https://doi.org/10.1177/2050640620919585.
Montano-Loza AJ, Corpechot C. Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy. Clin Gastroenterol Hepatol 2021;19:2241-2251. https://doi.org/10.1016/j.cgh.2020.06.062.
Cortez-Pinto H, Liberal R, Lopes S, Machado MV, Carvalho J, Dias T, et al. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J 2021;9:699-706. https://doi.org/10.1002/ueg2.12095.
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis. Am J Gastroenterol 2021;116:1913-1923. https://doi.org/10.14309/ajg.0000000000001280.
Kjærgaard K, Frisch K, Sørensen M, Munk OL, Hofmann AF, Horsager J, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. J Hepatol 2021;74:58-65. https://doi.org/10.1016/j.jhep.2020.07.028.
Li X, Liao M, Pan Q, Xie Q, Yang H, Peng Y, et al. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review. Eur J Gastroenterol Hepatol 2020;32:1116-1122. https://doi.org/10.1097/meg.0000000000001785.
Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-1594. https://doi.org/10.1136/gutjnl-2017-315259.
Trivedi PJ, Corpechot C, Pares A, Hirschfield GM. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology 2016;63:644-659. https://doi.org/10.1002/hep.28128.
Zapata MC, Pedersen MR. Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation. Clin Liver Dis 2022;19:219-221. https://doi.org/10.1002/cld.1192.
Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-146. https://doi.org/10.1016/s0168-8278(01)00092-7.
Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011;121:523-544. https://doi.org/10.1042/cs20110184.
Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, et al. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2007;2:155-177. https://doi.org/10.2174/157488407780598171.
Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015;62:S25-37. https://doi.org/10.1016/j.jhep.2015.02.023.
Lee S, Yoon S, Chung H, Ji SC, Yoon SH, Yu KS, et al. Pharmacokinetics of ursodeoxycholic acid in elderly volunteers compared with younger adults in a Korean population. J Clin Pharmacol 2019;59:1085-1092. https://doi.org/10.1002/jcph.1409.
Rodríguez-Carranza R. Ácido ursodesoxicólico: Litolítico. Vademécum Académico de Medicamentos. 6ta ed. México D.F.: McGraw Hill; 2015. p. https://accessmedicina.mhmedical.com/content.aspx?bookid=1552§ionid=90366868.
Achufusi TGO, Safadi AO, Mahabadi N. Ursodeoxycholic acid. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2022, StatPearls Publishing LLC.; 2022. Acceso 26 de diciembre de 2022. Disponible en https://pubmed.ncbi.nlm.nih.gov/31424887/.
Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid-Adverse effects and drug interactions. Aliment Pharmacol Ther 2003;18:963-972. https://doi.org/10.1046/j.1365-2036.2003.01792.x.
Belliveau PP, Nightingale CH, Qunitiliani R, Maderazo EG. Reduction in serum concentrations of ciprofloxacin after administration of ursodiol to a patient with hepatobiliary disease. Clin Infect Dis 1994;19:354-355. https://doi.org/10.1093/clinids/19.2.354.
Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-1199. https://doi.org/10.1053/jhep.2000.20240.
Axcan Pharma US. URSO 250®/URSO Forte®, (ursodiol tablets, USP) 250 mg & 500 mg. Draft U.S. package insert. Birmingham AL: Axcan Pharma US, Inc.; 2007. Acceso 20 de diciembre de 2022. Disponible en https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020675s013lbl.pdf.
Goet JC, Hirschfield GM. Guideline review: British Society of Gastroenterology/UK-PBC Primary biliary cholangitis treatment and management guidelines. Frontline Gastroenterol 2019;10:316-319. https://doi.org/10.1136/flgastro-2018-101109.
Axcan Pharma US. Highlights of prescribing information. URSO 250/URSO Forte (ursodiol) tablets. Birmingham AL: Axcan Pharma US, Inc.; 2009. Acceso 20 de diciembre de 2022. Disponible en https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020675s017lbl.pdf.
Melo D, Areia AL, Moura P. Primary biliary cholangitis first demonstrated in pregnancy: a case report. J Med Case Rep 2022;16:38. https://doi.org/10.1186/s13256-022-03260-7.
de Vries E, Beuers U. Management of cholestatic disease in 2017. Liver Int 2017;37:S123-129. https://doi.org/10.1111/liv.13306.
Poupon R, Chrétien Y, Chazouillères O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005;42:418-419. https://doi.org/10.1016/j.jhep.2004.08.029.
Efe C, Kahramanoğlu-Aksoy E, Yilmaz B, Ozseker B, Takci S, Roach EC, et al. Pregnancy in women with primary biliary cirrhosis. Autoimmun Rev 2014;13:931-935. https://doi.org/10.1016/j.autrev.2014.05.008.
Trivedi PJ, Kumagi T, Al-Harthy N, Coltescu C, Ward S, Cheung A, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2014;12:1179-1185. https://doi.org/10.1016/j.cgh.2013.11.030.
Floreani A, Infantolino C, Franceschet I, Tene IM, Cazzagon N, Buja A, et al. Pregnancy and primary biliary cirrhosis: a case-control study. Clin Rev Allergy Immunol 2015;48:236-242. https://doi.org/10.1007/s12016-014-8433-z.
Lopes IF, Palma-Dos Reis CR, Alves MJ, Calinas F, Borges MA. Primary biliary cholangitis: a rare diagnosis during pregnancy. Obstet Med 2022;15:273-275. https://doi.org/10.1177/1753495x211008290.
Arora A, Kumar A, Anand AC, Puri P, Dhiman RK, Acharya SK, et al. Indian National Association for the Study of the Liver-Federation of Obstetric and Gynaecological Societies of India position statement on management of liver diseases in pregnancy. J Clin Exp Hepatol 2019;9:383-406. https://doi.org/10.1016/j.jceh.2019.02.007.
Grand'Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can 2014;36:632-641. https://doi.org/10.1016/s1701-2163(15)30544-2.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
